Raymond James Financial’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Raymond James Financial’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$55.3M	Sell	433,132 -32,886	-7%	-$4.11M	0.02%	799
2025 Q4	$56.8M	Buy	466,018 +84,438	+22%	+$9.68M	0.02%	760
2025 Q3	$38.2M	Sell	381,580 -117,859	-24%	-$10.6M	0.01%	974
2025 Q2	$41.4M	Sell	499,439 -43,701	-8%	-$3.49M	0.01%	873
2025 Q1	$44M	Sell	543,140 -73,433	-12%	-$6.56M	0.02%	792
2024 Q4	$55.5M	Buy	+616,573	New	+$59.7M	0.02%	666

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Raymond James Financial's XBI Position: Q1 2026 in Review

Raymond James Financial reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 7.1% in Q1 2026, selling an estimated $4.11M and leaving 433,132 shares worth $55.3M. The position accounts for 0.02% of the portfolio, ranked #799.

Raymond James Financial first reported a position in XBI in Q4 2024 and has held it in 6 quarters since. The position peaked at $56.8M in Q4 2025. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Raymond James Financial held 433,132 shares of State Street SPDR S&P Biotech ETF worth $55.3M as of Q1 2026.
Raymond James Financial sold 32,886 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $4.11M.
State Street SPDR S&P Biotech ETF made up 0.02% of Raymond James Financial's portfolio in Q1 2026, its #799 holding.
Raymond James Financial first reported a position in State Street SPDR S&P Biotech ETF in Q4 2024 and has held it in 6 quarters since.
Raymond James Financial's State Street SPDR S&P Biotech ETF position peaked at $56.8M in Q4 2025.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.